

Clinical benefits for patients and caregivers



- Decelerate cognitive decline
- Improvement of memory and concentration
- Stay active in social life
- Live a fully independent life
- Reduced support from caregivers needed
- Prevent behavior symptoms and the destruction of personality
- Increase quality of life

Administration

Disorder	Daily dosage	Initiation of treatment	Treatment Duration	Route of administration
Vascular dementia	10 – 30 ml	as soon as possible	2 – 4 cycles / year 1 cycle = 5 days weekly / 4 weeks	<ul style="list-style-type: none">• IV injection for 3 min: Up to 10 ml undiluted• IV injection for 15 – 60 min: 10 ml - 50 ml diluted to at least 100 ml total volume with saline, Ringer solution for 5% glucose solution• 5 ml dosage (undiluted) can be administered intramuscularly
Alzheimer's disease	10 – 30 ml	as soon as possible	2 – 4 cycles / year 1 cycle = 5 days weekly / 4 weeks	
Stroke	20 – 50 ml	as soon as possible	10 – 21 days	
Traumatic brain injury	20 – 50 ml	as soon as possible	7 – 30 days	



Cerebrolysin® is a multi-modal neuropeptide drug that helps to maintain the independence of patients suffering from neurocognitive disorders



- 1 RUETHER, E., et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. International clinical psychopharmacology, 2001, 16. Jg., Nr. 5, S. 253-263
- 2 GUEKHT, Alla B., et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases, 2011, 20. Jg., nr. 4, S. 310-318
- 3 ALVAREZ, X. A., et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. European journal of neurology, 2006, 13. Jg., Nr. 1, S. 43-54
- 4 GAUTHIER, Serge, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dementia and geriatric cognitive disorders, 2015, 39. Jg., Nr. 5-6, S. 332-347
- 5 Chen, N., Yang, M., Guo, J., Zhou, M., Zhu, C., & He, L. (2013). Cerebrolysin for vascular dementia. Cochrane Database Syst. Rev, 1.

Copyright © 2018 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria.

ABBREVIATED PRESCRIBING INFORMATION: Cerebrolysin

Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin® concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC – CCDS Version 1.0/Jan 28 2014)

EVER Neuro Pharma GmbH
Oberburgau 3
4866 Unterach
Austria
www.everpharma.com
www.cerebrolysin.com

CERE/INT/06/2018/11



TBI

NEUROCOGNITIVE DISORDERS

STROKE

Effective treatment for
Neurocognitive Disorders
with Cerebrolysin®


Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.

Cerebrolysin – Treatment without limitations

Diagnostic problems



Lack of
time



Lack of
test instruments




Lack of
solid criteria/biomarkers

No matter of
stage of the disease

No matter of type
of neurocognitive disorder

No matter of course
of the disease

CEREBROLYSIN FITS TO ALL



CEREBROLYSIN FITS TO ALL

Cognitive
impairment

Activities
of daily living


Global
function

Behavior & psychiatric
symptoms

Cognitive impairment


Cerebrolysin significantly improves cognitive performance!

Early and long-term beneficial effects on cognitive performance



- Significant cognitive improvements with Cerebrolysin
- Immediate treatment effects during each treatment cycle
- Cerebrolysin shows highest effect after second treatment cycle
- Efficacy difference of 3.2 points in favour of Cerebrolysin on month 7 confirms long-term effects

Decelerate cognitive decline with Cerebrolysin




- Significant superiority of Cerebrolysin
- ADAS-cog+ least squares (LS) mean change from baseline was -10.6 points in the Cerebrolysin group vs. -4.4 points in the placebo group
- 6.2 points treatment difference in favour of Cerebrolysin

Activities of daily living


Prolong active and independent life with Cerebrolysin!

Cerebrolysin increases level of activities of daily living



- Significant superiority of Cerebrolysin in ADCS-ADL score
- Constant improvements in Cerebrolysin group while patients in placebo group are unchanged
- Even within the follow-up-period consistent enhancements in Cerebrolysin group

Regain independence with Cerebrolysin




- Best results with a daily dosage of 30 ml
- Dose of 30 ml Cerebrolysin exerts a beneficial effect on patients capabilities to cope with ADL
- Even in the follow-up time Cerebrolysin treated patients show better results than in the beginning

Alvarez triggered inclusion in the Austrian Alzheimer's disease guideline³

Global functions


Better quality of life for patients and caregivers with Cerebrolysin!

Phenomenal NNT of 2.9 with Cerebrolysin



- Treat 3 patients and one additional patient shows significant beneficial effects
- Positive benefit-risk relation in favour of Cerebrolysin
- NNT for benefit shows a significant global clinical change of 2.9
- Lowest NNT for harm with respect to risk (501)

100% higher quality of life with Cerebrolysin



- CIBIC+ assessment showed a significant shift toward improvement in the Cerebrolysin group when compared to placebo
- In Cerebrolysin group majority of patients showed improvement (75.3% vs. 37.4% in placebo group)
- In placebo group majority of patients remained unchanged
- Lines show exact this picture – Highest point of curve in the area of improvement in Cerebrolysin group vs. in the area of no change in the placebo group




Cochrane review “Use of Cerebrolysin in the treatment of vascular dementia” confirms the efficacy of Cerebrolysin in the therapy of cognitive impairment⁵

Behavior & psychiatric symptoms


Cerebrolysin improves behavior & neuropsychiatric symptoms!

Improvement of behavior problems which facilitate home care



- Significant improvements of behavior in Cerebrolysin group
- After 7 months Cerebrolysin treated patients still improved in the ADAS-noncog, while patients in the placebo group have worsened

Significant improvement of neuropsychiatric symptoms



- Improvements in the NPI score in all Cerebrolysin groups
- At month 6 all groups treated with Cerebrolysin significantly improved and maintained the beneficial effects of neuropsychiatric symptoms
- Placebo patients deteriorated from their baseline
- At all time points the dosage of 60 ml is the most effective one – even further improvements in the follow-up period was shown in this group